WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc., an emerging pharmaceutical company developing RNA interference (RNAi)-based therapeutics against genetically-defined targets in multiple disease areas, announced today the publication of a paper in Molecular Therapy: “Knockdown of ß-catenin with Dicer Substrate siRNAs Reduces Liver Tumor Burden in Vivo.” The data presented in Molecular Therapy demonstrate the potential therapeutic benefit achievable through the silencing of key oncogenes utilizing Dicerna’s unique approach to RNA interference.
Help employers find you! Check out all the jobs and post your resume.
